After Jiangsu Maixinlin Aviation Science And Technology Corp(688685) , A-Shares have been reduced by more than 10%. On May 22, Allgens Medical Technology Co.Ltd(688613) ( Allgens Medical Technology Co.Ltd(688613) ) disclosed that the shareholders of the company, Beijing Qilun Tianyou Venture Capital Co., Ltd. (hereinafter referred to as “Qilun Tianyou”), bioveda China RMB investment, Limited (hereinafter referred to as “bioveda”) and Jiaxing Huakong equity investment fund partnership (limited partnership) (hereinafter referred to as “Jiaxing Huakong”) planned to reduce the total shares of the company by no more than 10.56%. It is worth mentioning that the shares held by the above three shareholders were obtained before Allgens Medical Technology Co.Ltd(688613) initial public offering and listing, and were listed and circulated from May 23. This also means that as soon as the shareholding ban of the above three shareholders was lifted, they couldn’t wait to throw out a large proportion of the reduction plan. According to the calculation of the reporter of Beijing business daily, the above three shareholders intend to reduce their shares, corresponding to the market value of the listed company of 418 million yuanp align=”center”>
three shareholders plan to reduce their holdings by no more than 10.56%
Allgens Medical Technology Co.Ltd(688613) ‘s three original shareholders shall “form a group” to reduce their holdings, and the total reduction proportion shall not exceed 10.56%.
On May 22, Allgens Medical Technology Co.Ltd(688613) disclosed a “announcement on the share reduction plan of shareholders”. According to the “notification letter on the share reduction plan” recently received from shareholders Qilun Tianyou, bioveda and Jiaxing Huakong, due to their own capital arrangement, the three shareholders will reduce their holdings through centralized bidding and block trading according to the market conditions, and they plan to reduce their holdings by no more than 2.69%, 3% and 4.87% respectively.
After calculation, the total proposed reduction ratio of the above three shareholders shall not exceed 10.56%.
As of the disclosure date of the announcement, Qilun Tianyou, bioveda and Jiaxing Huakong held Allgens Medical Technology Co.Ltd(688613) 907%, 8.82% and 9.73% shares respectively.
It should be noted that the Allgens Medical Technology Co.Ltd(688613) shares held by three shareholders of Qilun Tianyou, bioveda and Jiaxing Huakong were acquired before the company’s initial public offering and listing, and were listed and circulated on May 23, 2022.
It is not difficult to see that as soon as the ban on shareholding was lifted, the above three shareholders threw out a large reduction plan.
Beijing Business Daily reporter noted that recently, many shareholders of listed companies plan to “form a group” to reduce their holdings by a large amount. For example, Jiangsu Maixinlin Aviation Science And Technology Corp(688685) may 17 disclosed that the company’s shareholder Ili Suxin investment fund partnership (limited partnership) and its concerted actor Nanjing Daofeng Investment Management Center (general partnership) and the company’s shareholder Suzhou Xinsi road Zhong’an venture capital partnership (limited partnership) planned to reduce the company’s shares by no more than 10.02%.
In addition, in the near future, the shareholders of Zhejiang Zoenn Design Co.Ltd(300901) , Beijing Transtrue Technology Inc(002771) two listed companies have also thrown out a large proportion of reduction plans. Among them, Zhejiang Zoenn Design Co.Ltd(300901) may 13 disclosed that the shareholder of the company, Xiamen Haojia venture capital partnership (limited partnership) and its persons acting in concert, Wenzhou Huayin equity investment partnership (limited partnership) plans to reduce the total shares of the company by no more than 9.63% Beijing Transtrue Technology Inc(002771) 5 on May 21, the disclosure announcement said that the company’s shareholders Hu Xiaozhou, Chen Ruiliang and Wu Lan planned to reduce their total holdings of no more than 6.96% of the company’s shares. For the reasons for the proposed reduction, Beijing Transtrue Technology Inc(002771) said that the shareholders’ personal capital arrangements.
Song Qinghui, an economist, told the Beijing Business Daily that generally speaking, the large reduction plan thrown out by the major shareholders of listed companies will attack the investment confidence of investors to a certain extent. “However, the share prices of listed companies will eventually move closer to the fundamentals.” Song Qinghui said.
share price all the way down from 137.85 yuan
After listing, Allgens Medical Technology Co.Ltd(688613) share price once hit a high of 137.85 yuan / share, but then went all the way down.
According to the data, Allgens Medical Technology Co.Ltd(688613) was founded in 2004 and landed on Kechuang board on May 21, 2021. The company is mainly engaged in the R & D, production and sales of mineralized collagen artificial bone repair materials, and realizes revenue and profit by selling mineralized collagen artificial bone repair materials to agents and terminal hospitals.
In 2021, Allgens Medical Technology Co.Ltd(688613) main business income came from the sales of mineralized collagen artificial bone repair materials.
It is understood that the initial price of Allgens Medical Technology Co.Ltd(688613) is 16.43 yuan / share. After the listing of the company, the share price briefly ushered in a wave of rise, and hit a high of 137.85 yuan / share on June 1, 2021. However, since then, Allgens Medical Technology Co.Ltd(688613) share price has fallen all the way and hit a low of 28.5 yuan / share on May 17 this year.
As of the closing on May 20, Allgens Medical Technology Co.Ltd(688613) share price was 29.69 yuan / share, with a total market value of 3.959 billion yuan. According to the calculation of the reporter of Beijing business daily, Allgens Medical Technology Co.Ltd(688613) the reduction proportion thrown out by the above three shareholders corresponds to the current market value of the company of 418 million yuan.
As the first annual report after the listing of the company, Allgens Medical Technology Co.Ltd(688613) 2021 had a good performance. During the reporting period, the total operating revenue was about 236 million yuan, an increase of 28.46% year-on-year; The corresponding attributable net profit was about 121 million yuan, a year-on-year increase of 35.8%; The corresponding net profit after non deduction was about 97.47 million yuan, a year-on-year increase of 18.34%.
However, in the first quarter of this year, Allgens Medical Technology Co.Ltd(688613) increased revenue without increasing profit.
Financial data show that in the first quarter of this year, Allgens Medical Technology Co.Ltd(688613) achieved a total operating revenue of about 45.89 million yuan, an increase of 25.1% year-on-year; The corresponding attributable net profit was about 13.15 million yuan, a year-on-year decrease of 27.32%; The corresponding net profit after non deduction was about 7.01 million yuan, a year-on-year decrease of 46.64%.
In response to relevant questions, the reporter of Beijing Business Daily called Allgens Medical Technology Co.Ltd(688613) Secretary Office for an interview, but no one answered the phone.
